Real‐world 10‐year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age‐related macular degeneration

Autor: Liv Erngaard, Torben Lykke Sørensen, Troels Brynskov, Inger Christine Munch, Tobias Malte Larsen
Rok vydání: 2019
Předmět:
Male
Vascular Endothelial Growth Factor A
real-world
retina
Visual acuity
genetic structures
Visual Acuity
Angiogenesis Inhibitors
0302 clinical medicine
Fluorescein Angiography
Aflibercept
Aged
80 and over
Best corrected visual acuity
General Medicine
wet age-related macular degeneration
Treatment Outcome
Intravitreal Injections
Female
medicine.symptom
Tomography
Optical Coherence
medicine.drug
medicine.medical_specialty
Prognostic factor
Recombinant Fusion Proteins
neovascular age-related macular degeneration
03 medical and health sciences
Ranibizumab
Age related
Ophthalmology
medicine
Humans
anti-vascular endothelial growth factor
Aged
Retrospective Studies
long-term
business.industry
Macular degeneration
medicine.disease
Choroidal Neovascularization
eye diseases
Regimen
Receptors
Vascular Endothelial Growth Factor
Wet Macular Degeneration
030221 ophthalmology & optometry
sense organs
business
030217 neurology & neurosurgery
Follow-Up Studies
Zdroj: Brynskov, T, Munch, I C, Larsen, T, Erngaard, L & Sørensen, T L 2020, ' Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration ', Acta Ophthalmologica, vol. 98, no. 2, pp. 132-138 . https://doi.org/10.1111/aos.14183
Brynskov, T, Munch, I C, Larsen, T M, Erngaard, L & Sørensen, T L 2020, ' Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration ', Acta Ophthalmologica, vol. 98, no. 2, pp. 132-138 . https://doi.org/10.1111/aos.14183
ISSN: 1755-3768
1755-375X
Popis: Purpose: To report 10-year, real-world experiences with intravitreal therapy (IVT) using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration (nAMD). Methods: Retrospective single-centre review of IVT-log 2007–2019 with a treatment-as-needed regimen and ETDRS visual acuity charts. Results: The 4,678 treatment-naïve eyes of 3,668 patients received a mean of 5.4 IVT in the first year and 4.0–4.3 IVT yearly thereafter. Baseline mean best corrected visual acuity (BCVA) was 57.9 (±16.4) letters (6/18) that improved a mean +2.1 (±0.2) letters at the first follow-up visit and gradually declined to −5.0 (±2.2) letters after 10 years. At baseline, there were 29% with BCVA ≥6/12. This proportion increased to 31–37% until year 9. There were 8% with BCVA loss of ≥3 lines at the first follow-up visit increasing to 34% after 10 years. Poorer baseline BCVA was associated with larger increase in BCVA (p
Databáze: OpenAIRE
Externí odkaz: